CN102365020B - 哒嗪酮化合物 - Google Patents
哒嗪酮化合物 Download PDFInfo
- Publication number
- CN102365020B CN102365020B CN201080014965.6A CN201080014965A CN102365020B CN 102365020 B CN102365020 B CN 102365020B CN 201080014965 A CN201080014965 A CN 201080014965A CN 102365020 B CN102365020 B CN 102365020B
- Authority
- CN
- China
- Prior art keywords
- substituted
- compound
- phenyl
- group
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C1C(C2=NN(*3CCC(C4)C4C*CCC3)C(*)=C(*)C2=O)=CC=C1 Chemical compound *C1C(C2=NN(*3CCC(C4)C4C*CCC3)C(*)=C(*)C2=O)=CC=C1 0.000 description 24
- SHFIBWPYWIMLJA-UHFFFAOYSA-N CC(C(C(N=C)=O)=N)=O Chemical compound CC(C(C(N=C)=O)=N)=O SHFIBWPYWIMLJA-UHFFFAOYSA-N 0.000 description 1
- YUGLEFYERNROCN-UHFFFAOYSA-O CC(C(C=C1)[NH2+]C=CC(C(C(Nc2ccccc2)=CC=N)=N)=O)C=C1C(N)=O Chemical compound CC(C(C=C1)[NH2+]C=CC(C(C(Nc2ccccc2)=CC=N)=N)=O)C=C1C(N)=O YUGLEFYERNROCN-UHFFFAOYSA-O 0.000 description 1
- ZXZRZTQXIHOREW-QGRKOZDTSA-N CC(CC(C1C#CCCC(C2)c3cccc(C(F)(F)F)c3)C=[O](C)(C3)[C@H]3/C1=C/C2=O)=C Chemical compound CC(CC(C1C#CCCC(C2)c3cccc(C(F)(F)F)c3)C=[O](C)(C3)[C@H]3/C1=C/C2=O)=C ZXZRZTQXIHOREW-QGRKOZDTSA-N 0.000 description 1
- ODJBJHOBECSQFW-UHFFFAOYSA-N CC(CC1)CC(C2)C12c1c(C)c(N(C=C2OC)N=C(C3=CC=NC3C3=CC=CCC3)C2=C)ccc1 Chemical compound CC(CC1)CC(C2)C12c1c(C)c(N(C=C2OC)N=C(C3=CC=NC3C3=CC=CCC3)C2=C)ccc1 ODJBJHOBECSQFW-UHFFFAOYSA-N 0.000 description 1
- LOKIITTYQLGTGK-UHFFFAOYSA-N CCOc(cccc1)c1NN=C(C(C)=O)C(C)=O Chemical compound CCOc(cccc1)c1NN=C(C(C)=O)C(C)=O LOKIITTYQLGTGK-UHFFFAOYSA-N 0.000 description 1
- GPWXIOMUUOBXQB-UHFFFAOYSA-N CN(C(C(C(C(OC)=C1)=O)=NN1c1cccc(-c2c[n](C)nc2)c1F)=O)OC Chemical compound CN(C(C(C(C(OC)=C1)=O)=NN1c1cccc(-c2c[n](C)nc2)c1F)=O)OC GPWXIOMUUOBXQB-UHFFFAOYSA-N 0.000 description 1
- WFTLHMOKLNFUDI-UHFFFAOYSA-N CN(C)c1ccc(C(F)(F)F)cc1N(C=C1)N=C(c2ccn[n]2-c2ccccc2)C1=O Chemical compound CN(C)c1ccc(C(F)(F)F)cc1N(C=C1)N=C(c2ccn[n]2-c2ccccc2)C1=O WFTLHMOKLNFUDI-UHFFFAOYSA-N 0.000 description 1
- QQXHSCCLPNZGDD-UHFFFAOYSA-N COC(N(c1cc(C(F)(F)F)ccc1)N=C1c2ccn[n]2-c2ccccc2)=CC1=O Chemical compound COC(N(c1cc(C(F)(F)F)ccc1)N=C1c2ccn[n]2-c2ccccc2)=CC1=O QQXHSCCLPNZGDD-UHFFFAOYSA-N 0.000 description 1
- FGMDUUOMAJWHGW-UHFFFAOYSA-N COC1=CN(c(cc(cc2)-[n]3nccc3)c2F)N=C(c2ccn[n]2C2=CC=CCC2)C1=C Chemical compound COC1=CN(c(cc(cc2)-[n]3nccc3)c2F)N=C(c2ccn[n]2C2=CC=CCC2)C1=C FGMDUUOMAJWHGW-UHFFFAOYSA-N 0.000 description 1
- KWDQRBQEOQARPF-UHFFFAOYSA-N COC1=CN(c(ccc(N(C2)CC2F)c2)c2F)N=C(c2ccn[n]2-c2ccccc2)C1=O Chemical compound COC1=CN(c(ccc(N(C2)CC2F)c2)c2F)N=C(c2ccn[n]2-c2ccccc2)C1=O KWDQRBQEOQARPF-UHFFFAOYSA-N 0.000 description 1
- HKZJQRGMURJKHV-UHFFFAOYSA-N COC1=CN(c2cccc(C3CCOCC3)c2F)N=C(C2=CC=CCN2c2ccccc2)C1=O Chemical compound COC1=CN(c2cccc(C3CCOCC3)c2F)N=C(C2=CC=CCN2c2ccccc2)C1=O HKZJQRGMURJKHV-UHFFFAOYSA-N 0.000 description 1
- BWAPJIHJXDYDPW-UHFFFAOYSA-N Cc(cc(c(C)c1)N)c1N Chemical compound Cc(cc(c(C)c1)N)c1N BWAPJIHJXDYDPW-UHFFFAOYSA-N 0.000 description 1
- NJZXGWRQZVQOTR-UWCQTGLRSA-N Cc1ccccc1N/C(/C(C(/C=C\Nc1cccc(C(F)(F)F)c1)=O)=N)=C\C=N Chemical compound Cc1ccccc1N/C(/C(C(/C=C\Nc1cccc(C(F)(F)F)c1)=O)=N)=C\C=N NJZXGWRQZVQOTR-UWCQTGLRSA-N 0.000 description 1
- FVIOUDBDJPKVJV-XPOPEFDLSA-N NNC(C(C(/C=C\Nc1cccc(C(F)(F)F)c1)=O)=N)=O Chemical compound NNC(C(C(/C=C\Nc1cccc(C(F)(F)F)c1)=O)=N)=O FVIOUDBDJPKVJV-XPOPEFDLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20220709P | 2009-02-05 | 2009-02-05 | |
| US61/202,207 | 2009-02-05 | ||
| US21392709P | 2009-07-30 | 2009-07-30 | |
| US61/213,927 | 2009-07-30 | ||
| PCT/US2010/000307 WO2010090737A1 (en) | 2009-02-05 | 2010-02-04 | Pyridazinone compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102365020A CN102365020A (zh) | 2012-02-29 |
| CN102365020B true CN102365020B (zh) | 2014-07-30 |
Family
ID=42398214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080014965.6A Active CN102365020B (zh) | 2009-02-05 | 2010-02-04 | 哒嗪酮化合物 |
Country Status (37)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009054791A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5 |
| JP5627574B2 (ja) * | 2008-06-03 | 2014-11-19 | インターミューン， インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
| ME02337B (me) * | 2009-02-05 | 2016-06-20 | Takeda Pharmaceuticals Co | Jedinjenja piridazinona |
| WO2011163355A1 (en) | 2010-06-24 | 2011-12-29 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors |
| WO2012009194A1 (en) * | 2010-07-12 | 2012-01-19 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
| EP2601192B1 (en) | 2010-08-04 | 2017-03-01 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| US8883788B2 (en) | 2010-08-04 | 2014-11-11 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring compound |
| WO2012018059A1 (ja) | 2010-08-04 | 2012-02-09 | 武田薬品工業株式会社 | 複素環化合物 |
| EP2604597B1 (en) * | 2010-08-10 | 2017-01-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a |
| JP2013234123A (ja) * | 2010-09-03 | 2013-11-21 | Taisho Pharmaceutical Co Ltd | ３−ピラゾリル−２−ピリドン誘導体 |
| MX2013009575A (es) | 2011-02-18 | 2014-10-14 | Exonhit Therapeutics Sa | Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a). |
| EP2687529B1 (en) | 2011-03-16 | 2016-07-13 | Takeda Pharmaceutical Company Limited | Condensed heterocyclic compound |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| JP6153513B2 (ja) * | 2011-08-22 | 2017-06-28 | 武田薬品工業株式会社 | 哺乳類中のホスホジエステラーゼ（ｐｄｅ１０ａ）を定量的に画像化する放射性トレーサとしての放射標識された化合物及びその用途 |
| US9212147B2 (en) | 2011-11-15 | 2015-12-15 | Takeda Pharmaceutical Company Limited | Dihydroxy aromatic heterocyclic compound |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| JP6364420B2 (ja) | 2013-02-21 | 2018-07-25 | 武田薬品工業株式会社 | ピリダジノン化合物の製造方法 |
| WO2014142322A1 (ja) | 2013-03-15 | 2014-09-18 | 第一三共株式会社 | ベンゾチオフェン誘導体 |
| WO2015006689A1 (en) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
| HK1225382A1 (zh) * | 2013-09-12 | 2017-09-08 | Alios Biopharma, Inc. | 噠嗪酮化合物及其用途 |
| PE20160661A1 (es) | 2013-09-12 | 2016-08-05 | Alios Biopharma Inc | Compuesto de azapiridona y sus usos de los mismos |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| ES2544869B2 (es) * | 2014-03-04 | 2016-01-18 | Universidade De Vigo | Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa |
| US10231929B2 (en) | 2014-03-18 | 2019-03-19 | Takeda Pharmaceutical Company Limited | Solid dispersion |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| US10208045B2 (en) | 2015-03-11 | 2019-02-19 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| WO2016191935A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| CN107428721B (zh) | 2015-12-22 | 2020-07-28 | 江苏恒瑞医药股份有限公司 | 苯并哌啶类衍生物、其制备方法及其在医药上的应用 |
| US10736894B2 (en) | 2018-02-15 | 2020-08-11 | Ovid Therapeutics Inc. | Methods of treating developmental syndromes with PDE10A inhibitors |
| CN108498868B (zh) * | 2018-04-03 | 2020-09-15 | 北京大学口腔医学院 | 具有细胞外基质电学拓扑特征的带电复合膜及其制备方法 |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| WO2019241787A1 (en) * | 2018-06-15 | 2019-12-19 | The Regents Of The University Of Colorado A Body Corporate | Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use |
| JP2022501335A (ja) * | 2018-09-28 | 2022-01-06 | 武田薬品工業株式会社 | 自閉症スペクトラム障害を治療または予防するためのバリポデクト（Ｂａｌｉｐｏｄｅｃｔ） |
| MX2019008440A (es) | 2019-07-15 | 2021-01-18 | Dva Farma Mexicana S A De C V | Composiciones de recubrimientos en pelicula para tabletas con brillantez incrementada, procedimiento de preparacion y aplicacion. |
| EP3805206A1 (en) * | 2019-10-08 | 2021-04-14 | Novaled GmbH | Compound and an organic semiconducting layer, an organic electronic device, a display device and a lighting device comprising the same |
| GB202002926D0 (en) | 2020-02-28 | 2020-04-15 | Benevolentai Tech Limited | Compositions and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877175A (en) * | 1995-03-29 | 1999-03-02 | Knoll Aktiengesellschaft | Pharmaceutical compositions |
| US20040009988A1 (en) * | 2000-06-01 | 2004-01-15 | Nerina Dodic | Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors |
| CN102239162A (zh) * | 2008-12-04 | 2011-11-09 | 弗·哈夫曼-拉罗切有限公司 | 哒嗪酮衍生物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0011693A1 (de) | 1978-10-03 | 1980-06-11 | Ciba-Geigy Ag | Neue N-(trifluormethansulfonylaminophenyl)-substituierte N-Heterocyclen, ihre Herstellung, sie enthaltende Mittel und ihre Verwendung zur Beeinflussung des Pflanzenwachstums |
| FR2648135B1 (fr) * | 1989-06-07 | 1991-09-27 | Pf Medicament | Derives de phenyl-1-dihydro-1,4 amino-3 oxo-4 pyridazines, leur preparation et leur application en therapeutique |
| CA2340230C (en) | 1998-08-14 | 2008-03-11 | Nihon Nohyaku Co., Ltd. | Pyridazinone derivatives having cell adhesion inhibiting activity |
| US20070060606A1 (en) | 1999-10-07 | 2007-03-15 | Robertson Harold A | Compounds and methods for modulating phosphodiesterase 10A |
| ATE346064T1 (de) | 2000-09-15 | 2006-12-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinasehemmer |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| CA2568929A1 (en) | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| EP1769092A4 (en) | 2004-06-29 | 2008-08-06 | Europ Nickel Plc | IMPROVED LIXIVIATION OF BASE METALS |
| AU2005323794B2 (en) | 2005-01-07 | 2012-07-19 | Pfizer Products Inc. | Heteroaromatic quinoline compounds and their use as PDE10 inhibitors |
| WO2006095666A1 (ja) * | 2005-03-07 | 2006-09-14 | Kyorin Pharmaceutical Co., Ltd. | ピラゾロピリジン－４－イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤 |
| CA2654394A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| WO2010000020A1 (en) | 2008-06-30 | 2010-01-07 | Cathrx Ltd | A catheter |
| TW201030001A (en) | 2008-11-14 | 2010-08-16 | Amgen Inc | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors |
| TWI396689B (zh) | 2008-11-14 | 2013-05-21 | Amgen Inc | 作為磷酸二酯酶１０抑制劑之吡衍生物 |
| ME02337B (me) | 2009-02-05 | 2016-06-20 | Takeda Pharmaceuticals Co | Jedinjenja piridazinona |
| US9187455B2 (en) | 2009-02-23 | 2015-11-17 | Hoffmann-La Roche Inc. | Substituted pyridazines as PDE10A inhibitors |
| US8415381B2 (en) | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
| US8883788B2 (en) * | 2010-08-04 | 2014-11-11 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring compound |
| EP2604597B1 (en) * | 2010-08-10 | 2017-01-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a |
-
2010
- 2010-02-04 ME MEP-2016-194A patent/ME02337B/me unknown
- 2010-02-04 HR HRP20160065TT patent/HRP20160065T1/hr unknown
- 2010-02-04 CA CA2751565A patent/CA2751565C/en active Active
- 2010-02-04 SI SI201031103T patent/SI2393360T1/sl unknown
- 2010-02-04 EA EA201171004A patent/EA020690B1/ru not_active IP Right Cessation
- 2010-02-04 GE GEAP201012363A patent/GEP20146004B/en unknown
- 2010-02-04 HU HUE10738857A patent/HUE027478T2/en unknown
- 2010-02-04 US US12/656,605 patent/US8916566B2/en active Active
- 2010-02-04 NZ NZ594851A patent/NZ594851A/xx unknown
- 2010-02-04 CN CN201080014965.6A patent/CN102365020B/zh active Active
- 2010-02-04 EP EP15192646.6A patent/EP3006031A1/en not_active Withdrawn
- 2010-02-04 BR BRPI1008498A patent/BRPI1008498B8/pt active IP Right Grant
- 2010-02-04 WO PCT/US2010/000307 patent/WO2010090737A1/en not_active Ceased
- 2010-02-04 MY MYPI2011003610A patent/MY170610A/en unknown
- 2010-02-04 US US13/148,172 patent/US8354411B2/en active Active
- 2010-02-04 PL PL10738857T patent/PL2393360T3/pl unknown
- 2010-02-04 AR ARP100100304A patent/AR075238A1/es active IP Right Grant
- 2010-02-04 SG SG2011054491A patent/SG173175A1/en unknown
- 2010-02-04 KR KR1020117020556A patent/KR101730665B1/ko active Active
- 2010-02-04 RS RS20150859A patent/RS54504B1/sr unknown
- 2010-02-04 MX MX2011008305A patent/MX2011008305A/es active IP Right Grant
- 2010-02-04 PE PE2011001434A patent/PE20110991A1/es active IP Right Grant
- 2010-02-04 AU AU2010211050A patent/AU2010211050B2/en active Active
- 2010-02-04 UY UY0001032417A patent/UY32417A/es not_active Application Discontinuation
- 2010-02-04 JO JOP/2010/0038A patent/JO3114B1/ar active
- 2010-02-04 EP EP10738857.1A patent/EP2393360B1/en active Active
- 2010-02-04 ES ES10738857.1T patent/ES2561181T3/es active Active
- 2010-02-04 DK DK10738857.1T patent/DK2393360T3/en active
- 2010-02-04 JP JP2011549157A patent/JP5659166B2/ja active Active
- 2010-02-04 TW TW099103286A patent/TWI457333B/zh active
- 2010-02-04 MA MA34133A patent/MA33072B1/fr unknown
-
2011
- 2011-07-18 IL IL214137A patent/IL214137A/en active IP Right Grant
- 2011-07-22 TN TN2011000362A patent/TN2011000362A1/fr unknown
- 2011-08-03 DO DO2011000254A patent/DOP2011000254A/es unknown
- 2011-08-17 CR CR20110440A patent/CR20110440A/es unknown
- 2011-08-18 ZA ZA2011/06074A patent/ZA201106074B/en unknown
- 2011-08-23 CO CO11106877A patent/CO6410258A2/es active IP Right Grant
- 2011-09-05 EC EC2011011305A patent/ECSP11011305A/es unknown
-
2012
- 2012-07-06 US US13/543,207 patent/US8778944B2/en active Active
- 2012-07-06 US US13/543,332 patent/US8435995B2/en active Active
- 2012-07-06 US US13/543,296 patent/US8513251B2/en active Active
-
2014
- 2014-10-17 US US14/517,313 patent/US9550756B2/en active Active
-
2016
- 2016-01-08 SM SM201600008T patent/SMT201600008B/it unknown
- 2016-12-13 US US15/377,149 patent/US20170114044A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877175A (en) * | 1995-03-29 | 1999-03-02 | Knoll Aktiengesellschaft | Pharmaceutical compositions |
| US20040009988A1 (en) * | 2000-06-01 | 2004-01-15 | Nerina Dodic | Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors |
| CN102239162A (zh) * | 2008-12-04 | 2011-11-09 | 弗·哈夫曼-拉罗切有限公司 | 哒嗪酮衍生物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102365020B (zh) | 哒嗪酮化合物 | |
| EP2604597B1 (en) | Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a | |
| EP2602254B1 (en) | Heterocyclic compound | |
| CN101541801A (zh) | 稠杂环衍生物及其用途 | |
| HK1164642B (en) | Pyridazinone compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |